Mergers & Acquisitions ·
Supernus completes merger with Indivior, borrows $650M to fund $1B special dividend
INDVSupernus, Inc.
Supernus, Inc. completed its previously announced business combination with Indivior Pharmaceuticals, Inc., renaming the combined entity Supernus, Inc. and beginning trading on Nasdaq under the ticker symbol SUPN on November 3, 2026. To finance a $1 billion special cash dividend to former Indivior stockholders, the company drew down on a new $650 million senior secured term loan facility provided by Citibank N.A., with the remainder funded by existing cash. Former Indivior shareholders own approximately 56.5% of the combined company, while former Supernus shareholders own 43.5%. Jack Khattar was appointed CEO and Tony Kingsley serves as Board Chair. The company operates in the central nervous system biopharmaceutical industry.